1. Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 2011;28:91–109.  Show 2. Committee on infectious diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694–1701. 3. Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr
Med Res Opin 2010;26:2175–2181. 4. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial
virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–540. 5. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al.
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215–1224. 6. Tulloh R, Marsh M,
Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003;13:420–423. 7. Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009;94:785–789. 8. Subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118:1774–1793. 9. Kneyber Mcj EW, Steyerberg R, de Groot HA, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr
2000;89:654–660. 10. Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child 1981;135:512–515. 11. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial
virus immune globulin prophylaxis. Pediatrics 1997;99:93–99. 12. Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al. The Cardiac Study Group. Respiratory syncytial
virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998;133:492–499. 13. Samson L.
Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14:521–532. 14. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011;28:110–125. 15. Weisman LE. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. Cardiovasc Hematol Agents Med Chem 2009;7:223–233. 16. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 2011;9:27–32. 17. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010;16:46–58. 18. Meissner HC, Long S. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1447–1452. 19. Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev 2009;10:143–147. 20. Smart KA, Lanctt KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ 2010;13:453–463. 21. Prescott WA, Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010;28:279–293. 22. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;5 05 [Epub ahead of print]. 23. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003;26:283–291. 24. Null D, Pollara B, Dennehy PH, Steichen J, Snchez PJ, Givner LB, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005;24:1021–1023. 25. Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010;51:185–188. 26. DeVincenzo JP, Hall CB, Kimberlin DW, Snchez PJ, Rodriguez WJ, Jantausch BA, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004;190:975–978. 27. Georgescu G, Chemaly RF. Palivizumab: where to from here? Expert Opin Biol Ther 2009;9:139–147. 28. Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr 2010;6:296–300. 29. Cingoz O. Motavizumab. MAbs 2009;1:439–442. 30. Gill MA, Welliver RC. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin Biol Ther 2009;9:1335–1345. 31. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous
trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435–448. 32. Murphy BR, Walsh EE. Formalin-inactivated
respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988;26:1595–1597. 33. Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007;179:5415–5424. 34. Adair BM. Nanoparticle vaccines against respiratory viruses. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:405–414. 35. Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009;29:725–739. 36. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010;6:482–492. Which is the best preventative currently available for RSV?A drug called palivizumab (pah-lih-VIH-zu-mahb) is available to prevent severe RSV illness in certain infants and children who are at high risk for severe disease.
What medication is given to a child with RSV?Pavlivimab is a drug approved to prevent severe RSV in certain infants and children at high risk for severe disease. The drug doesn't cure RSV, is not used to treat children who already have severe RSV and can't prevent RSV infection. It is given as monthly injections during the RSV season.
How do you prevent respiratory syncytial virus in babies?RSV Prevention. Avoid kissing your baby if you have cold symptoms.. Clean and disinfect hard surfaces.. Don't let anyone smoke around your baby.. If possible, keep your baby away from anyone, including siblings, with cold symptoms.. Keep your baby away from crowds.. Ask people to wash their hands before they touch your baby.. What is the standard treatment for RSV?Most RSV infections go away on their own in a week or two. There is no specific treatment for RSV infection, though researchers are working to develop vaccines and antivirals (medicines that fight viruses).
|
